Equity Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock Option Plans

A summary of the status of the Company’s option plans as of March 31, 2016 and changes during the period then ended is presented below:

	Three months ended March 31, 2016
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		10,134,829		$	8.20
Granted		1,711,575			14.45
Exercised		(332,984	)		0.17
Forfeited and cancelled		(24,620	)		16.54
Outstanding as of March 31, 2016		11,488,800			9.35
Exercisable options		5,871,196			4.18
Vested and expected to vest		11,303,362		$	9.27

Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model

The fair value of share-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions: 

	Three months ended March 31,				Year ended December 31,
	2016	2015			2015
	Unaudited				Audited
Expected term (years)	6.25		6.25		6.25
Expected volatility	59.80%-60.19%		65.80	%	59.00%-65.80%
Risk-free interest rate	1.52%-1.88%		1.90	%	1.74%-2.05%
Dividend yield	0%	0%			0%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expenses related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2016 and 2015 and the year ended December 31, 2015 were:

	Three months ended March 31,				Year ended December 31,
	2016		2015		2015
	Unaudited				Audited
Cost of revenues	$	141	$	13	$	174
Research, development and clinical trials		763		421		2,529
Sales and marketing		1,290		408		2,496
General and administrative		3,262		970		6,661
Total share-based compensation expense	$	5,456	$	1,812	$	11,860